Roche MS drug results boost late-stage chances
by on Oct.20, 2011, under Health and Fitness
Swiss drugmaker Roche Holding said a mid-phase study found its ocrelizumab drug maintained significant reduction in disease activity for multiple sclerosis patients for almost two years, boosting its chances of success in late-stage trials.
View full post on Yahoo! Health News
